Creo Medical Group PLC - Chepstow, Wales-based medical device company focused on surgical endoscopy - Says its Speedboat Inject endoscopy product has been cleared for use in the entire gastrointestinal tract within European markets. Speedboat Inject is already cleared for full use in the gastrointestinal tract for the cutting and coagulation of soft tissue using radio frequency and microwave energy in the US and Asia Pacific regions. It is used for the prevention and treatment of bowel cancer. Adds it already has a ‘healthy pipeline’ of clinicians ready to use the Speedboat Inject device for upper gastrointestinal procedures across Europe, with demonstrations, training and procedures already planned.

Chief Executive Officer Craig Gulliford says: ‘This clearance opens up possibilities not only to increase the caseloads of existing users, but primarily to introduce Speedboat to a large base of new users.’

Current stock price: 35.70 pence, up 12% on Monday

12-month change: down 61%

Copyright 2023 Alliance News Ltd. All Rights Reserved.